Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLRX NASDAQ:GLTO NASDAQ:LEXX NASDAQ:LPCN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLRXBioLineRx$3.56-2.5%$4.51$2.30▼$35.02$15.17M1.1536,466 shs48,591 shsGLTOGalecto$3.38+3.7%$3.43$2.01▼$15.13$4.46M1.3532,552 shs10,032 shsLEXXLexaria Bioscience$0.85+1.8%$0.92$0.79▼$4.38$16.53M0.79203,770 shs64,466 shsLPCNLipocine$2.93-1.7%$3.20$2.68▼$6.17$15.88M1.2436,327 shs5,978 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLRXBioLineRx0.00%-8.01%-24.26%+15.21%-87.95%GLTOGalecto0.00%+4.81%-4.14%+21.80%-74.00%LEXXLexaria Bioscience0.00%-0.62%-4.08%-21.40%-73.00%LPCNLipocine0.00%-6.98%-10.40%+0.34%-33.56%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLRXBioLineRx2.201 of 5 stars3.83.00.00.00.60.01.3GLTOGalecto3.0316 of 5 stars3.53.00.00.02.51.71.3LEXXLexaria Bioscience2.3219 of 5 stars3.52.00.00.00.63.30.6LPCNLipocine2.6312 of 5 stars3.55.00.00.01.90.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLRXBioLineRx 3.50Strong Buy$26.00630.34% UpsideGLTOGalecto 3.00Buy$10.00195.86% UpsideLEXXLexaria Bioscience 3.00Buy$4.00373.37% UpsideLPCNLipocine 3.00Buy$9.00207.17% UpsideCurrent Analyst Ratings BreakdownLatest GLTO, LPCN, LEXX, and BLRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/29/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$5.00 ➝ $4.007/1/2025LEXXLexaria BioscienceHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.006/27/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/17/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/10/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.005/30/2025BLRXBioLineRxJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Strong-Buy5/29/2025LPCNLipocineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$8.005/28/2025BLRXBioLineRxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLRXBioLineRx$28.94M0.52N/AN/A$4.04 per share0.88GLTOGalectoN/AN/AN/AN/A$10.99 per shareN/ALEXXLexaria Bioscience$615.92K26.83N/AN/A$0.48 per share1.76LPCNLipocine$11.20M1.42N/AN/A$3.93 per share0.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLRXBioLineRx-$9.22M-$8.80N/AN/AN/A-15.21%-23.93%-6.80%8/14/2025 (Estimated)GLTOGalecto-$21.44M-$13.13N/AN/AN/AN/A-115.70%-95.42%8/11/2025 (Estimated)LEXXLexaria Bioscience-$5.80M-$0.67N/AN/AN/A-1,849.19%-157.22%-133.69%N/ALPCNLipocine$10K-$0.87N/A∞N/AN/A-23.59%-21.91%N/ALatest GLTO, LPCN, LEXX, and BLRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025BLRXBioLineRx-$0.35N/AN/AN/A$0.66 millionN/A8/14/2025Q2 2025LPCNLipocine-$0.41N/AN/AN/A$0.23 millionN/A8/5/2025Q2 2025GLTOGalectoN/A-$2.60N/A-$2.60N/AN/A8/5/2025Q2 2025LPCNLipocine-$0.41-$0.41N/A-$0.41$1.00 million$0.62 million7/14/2025Q3 2025LEXXLexaria Bioscience-$0.15-$0.21-$0.06-$0.21$0.17 million$0.17 million5/27/2025Q1 2025BLRXBioLineRx-$0.84$1.39+$2.23$1.39$7.72 million$11.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLRXBioLineRxN/AN/AN/AN/AN/AGLTOGalectoN/AN/AN/AN/AN/ALEXXLexaria BioscienceN/AN/AN/AN/AN/ALPCNLipocineN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLRXBioLineRx0.372.272.04GLTOGalectoN/A4.964.96LEXXLexaria BioscienceN/A3.903.90LPCNLipocineN/A12.7112.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLRXBioLineRx1.56%GLTOGalecto14.20%LEXXLexaria Bioscience13.06%LPCNLipocine9.11%Insider OwnershipCompanyInsider OwnershipBLRXBioLineRx1.10%GLTOGalecto10.80%LEXXLexaria Bioscience26.40%LPCNLipocine6.35%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLRXBioLineRx404.26 million4.22 millionOptionableGLTOGalecto401.32 million1.18 millionOptionableLEXXLexaria Bioscience719.56 million14.40 millionNot OptionableLPCNLipocine105.42 million5.08 millionNo DataGLTO, LPCN, LEXX, and BLRX HeadlinesRecent News About These CompaniesLipocine Announces Financial Results for the Second Quarter Ended June 30, 2025August 5, 2025 | prnewswire.comLipocine doses first patient in phase 3 trial for oral PPD treatmentJune 28, 2025 | uk.investing.comLipocine begins dosing in Phase III postpartum depression trial of LPCN 1154June 27, 2025 | msn.comLipocine Begins Phase 3 Trial for LPCN 1154June 26, 2025 | tipranks.comLipocine Inc.: Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum DepressionJune 26, 2025 | finanznachrichten.deLipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum DepressionJune 26, 2025 | prnewswire.comLipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025June 23, 2025 | prnewswire.comLe partenaire de Lipocine dépose une demande d’approbation au Canada pour un médicament TRT oralJune 9, 2025 | fr.investing.comLipocine annonce le dépôt d'une demande d'autorisation de mise sur le marché pour TLANDO au CanadaJune 9, 2025 | zonebourse.comZLipocine Announces Filing of New Drug Submission for TLANDO® in CanadaJune 9, 2025 | prnewswire.comLe LPCN 1148 de Lipocine mis en avant dans l'édition de juin 2025 de HepatologyMay 23, 2025 | zonebourse.comZLipocine’s LPCN 1148 Gains Fast Track DesignationMay 22, 2025 | tipranks.comLipocine's LPCN 1148 Highlighted in the June 2025 Edition of HepatologyMay 22, 2025 | prnewswire.comLipocine to Present at A.G.P. Healthcare ShowcaseMay 14, 2025 | tipranks.comLipocine to Present at A.G.P.'s Annual Healthcare Company ShowcaseMay 14, 2025 | prnewswire.comLipocine Reports Q1 2025 Financial ResultsMay 8, 2025 | tipranks.comLipocine Announces Financial Results for the First Quarter Ended March 31, 2025May 8, 2025 | prnewswire.comLipocine inks license and supply agreement for TLANDO in BrazilMay 7, 2025 | msn.comLipocine s’associe à Aché pour commercialiser TLANDO au BrésilMay 7, 2025 | fr.investing.comLipocine Inc. annonce un accord de licence et d'approvisionnement pour Tlando® au BrésilMay 7, 2025 | zonebourse.comZNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGLTO, LPCN, LEXX, and BLRX Company DescriptionsBioLineRx NASDAQ:BLRX$3.56 -0.09 (-2.47%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$3.56 0.00 (0.00%) As of 08/8/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.Galecto NASDAQ:GLTO$3.38 +0.12 (+3.68%) Closing price 08/8/2025 02:48 PM EasternExtended Trading$3.40 +0.02 (+0.71%) As of 08/8/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.Lexaria Bioscience NASDAQ:LEXX$0.84 +0.02 (+1.81%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$0.83 -0.01 (-1.30%) As of 08/8/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.Lipocine NASDAQ:LPCN$2.93 -0.05 (-1.68%) Closing price 08/8/2025 03:59 PM EasternExtended Trading$2.96 +0.02 (+0.85%) As of 08/8/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/04 - 08/08 Rocket Lab Reports Q2 Results: Is the Bull Thesis Still Intact? Airbnb Beats Earnings, But the Growth Story Is Losing Altitude Dutch Bros Just Flipped the Script With a Massive Earnings Beat Amazon Takes an Equity Stake in IonQ—Any Upside Potential? D-Wave Delivers Growth Shock—Investors Eye Quantum Future Is Eli Lilly’s 14% Post-Earnings Slide a Buy-the-Dip Opportunity? Constellation Energy’s Earnings Beat Signals a New Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.